This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Anemias  • Alert me on articles by topic

Heather J. Miller, MD; James Hu, MD; Johanna K. Valentine, MD; Preston S. Gable, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Management of iron deficiency anemia requires iron replacement with oral ferrous sulfate or ferrous gluconate. Many patients cannot tolerate or absorb these preparations because of gastrointestinal adverse effects. Iron dextran is approved by the Food and Drug Administration (FDA) for parenteral treatment of iron deficiency anemia and is the drug of choice for treating adults. While iron dextran is generally safe and effective, there are a variety of adverse effects including arthralgias, myalgias, nausea and vomiting, anaphylaxis, and death.¹ Intravenous (IV) ferric sodium gluconate (Ferrlecit; Sanofi-Aventis, Dagenham, England) is FDA approved for the treatment of iron deficiency anemia associated with patients with end-stage renal disease who are hemodialysis dependent but is not approved for the treatment of iron deficiency anemia associated with other patient populations. We examined the efficacy and tolerability of this compound in . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Iron Deficiency Anemia
Clark
Nutr Clin Pract 2008;23:128-141.
ABSTRACT | FULL TEXT